Clinical trial • Phase IV • Endocrinology

Estradiol for Turner syndrome

Phase IV trial of Estradiol for Turner syndrome.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Turner syndrome
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
18-09-2024
First CTIS Authorization Date
08-10-2024

Trial design

Oral estradiol (Estrofem, film-coated tablets) versus transdermal estradiol (Divigel 1 mg gel); dose and schedule not specified in the available record-controlled Phase IV trial in Denmark.

Comparator
Oral estradiol (Estrofem, film-coated tablets) versus transdermal estradiol (Divigel 1 mg gel); dose and schedule not specified in the available record
Target Sample Size
100

Eligibility

Recruits 100 No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling for vulnerable populations is not described..

Pregnancy Exclusion
Pregnancy
Vulnerable Population
No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling for vulnerable populations is not described.

Inclusion criteria

  • {"criterion_text":"- Diagnosis of Turner syndrome regardless of karyotype (Turner syndrome)\n- Age 18-50 years (Turner syndrome and healthy controls)\n- Already receiving estrogen treatment (Turner syndrome)\n- Female (healthy controls)\n- Previously healthy (healthy controls)\n- Not receiving any medication (healthy controls)\n- Not using any form of contraceptive pills (healthy controls)\n- No mental or psychiatric disorders (healthy controls)"}

Exclusion criteria

  • {"criterion_text":"- Active systemic chronic diseases\n- Known or suspected breast cancer\n- Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n- Untreated endometrial hyperplasia\n- Current or previous venous thromboembolism\n- Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n- Known hypersensitivity to the medications used\n- Pregnancy\n- Menopause (healthy controls only)"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Body composition: measured by bio impedance","definition_or_measurement_approach":"measured by bio impedance"}
  • {"endpoint_text":"- Blood test values: changes in the blood test values from baseline within the areas of metabolism, endocrinology, cardiovascular function, and coagulation","definition_or_measurement_approach":"changes in blood test values from baseline within areas of metabolism, endocrinology, cardiovascular function, and coagulation"}
  • {"endpoint_text":"- Cardiovascular status: 24-hour ambulatory blood pressure monitoring and arterial stiffness (measured by SphygmoCor)","definition_or_measurement_approach":"24-hour ambulatory blood pressure monitoring and arterial stiffness measured by SphygmoCor"}
  • {"endpoint_text":"- Muscle quality: MR scan of both quadriceps measuring muscle cross-sectional area (CSA) and fat content of the muscle. Maximal isometric muscle strength of both quadriceps (functional muscle tests). Muscle quality = maximum quadriceps strength measured in nM/muscle CSA.","definition_or_measurement_approach":"MR scan of quadriceps measuring muscle CSA and fat content; maximal isometric quadriceps strength (functional tests); muscle quality defined as maximum quadriceps strength in nM divided by muscle CSA"}
  • {"endpoint_text":"- Quadriceps strength test: maximal isometric muscle strength of both quadriceps measured simultaneously","definition_or_measurement_approach":"maximal isometric muscle strength of both quadriceps measured simultaneously"}
  • {"endpoint_text":"- Isometric hand strength test: maximal hand strength measured in kilograms","definition_or_measurement_approach":"maximal hand strength measured in kilograms"}
  • {"endpoint_text":"- Fitness: maximal oxygen uptake measured by a VO2max test","definition_or_measurement_approach":"maximal oxygen uptake measured by a VO2max test"}
  • {"endpoint_text":"- Bones: bone mineral density as measured by a DEXA scan","definition_or_measurement_approach":"bone mineral density measured by DEXA scan"}
  • {"endpoint_text":"- Jumping heigth: maximal jumping heigth measured in centimeters","definition_or_measurement_approach":"maximal jumping height measured in centimeters"}

Secondary endpoints

  • {"endpoint_text":"- Self-reported health-related quality of life and functioning (SF-36)","definition_or_measurement_approach":"Self-reported health-related quality of life and functioning measured by SF-36"}
  • {"endpoint_text":"- Self-reported quality of life (WHOQoL-Bref)","definition_or_measurement_approach":"Self-reported quality of life measured by WHOQoL-Bref"}
  • {"endpoint_text":"- Subjective assesment of the medication after 6 months of oral and six months of transdermal treatment","definition_or_measurement_approach":"Subjective assessment of the medication after 6 months of oral and 6 months of transdermal treatment"}

Recruitment

Planned Sample Size
100
Recruitment Window Months
60
Consent Approach
Subject information and informed consent forms are listed (L1_SIS patients, L1_SIS controls, L1_ICF patients, L1_ICF controls, L1_ICF_biobank documents). Informed consent is required from adult participants; no assent or proxy consent procedures for minors/vulnerable groups are described.

Geography

Total Number Of Sites
1
Total Number Of Participants
100

Denmark

Earliest CTIS Part Ii Submission Date
30-09-2024
Latest Decision Or Authorization Date
08-10-2024
Processing Time Days
8
Number Of Sites
1
Number Of Participants
100

Sites

Site Name
Department of Endocrinology and Internal Medicine, Aarhus University Hospital
Department Name
Endocrinology and Internal Medicine
Contact Person Name
Camilla Mains Balle
Contact Person Email
camibl@clin.au.dk

Sponsor

Primary sponsor

Full Name
Region Midtjylland
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"sponsorDuties code 1","organisation_type":"Educational Institution"}

Investigational products

Investigational Product Name
Estrofem, filmovertrukne tabletter
Active Substance
Estradiol
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised (marketing authorisation number 06697, Denmark)
Dose Levels
maxDailyDoseAmount: 10 mg; maxTotalDoseAmount: 2100 mg; maxTreatmentPeriod: 7 (timeUnitCode 3)
Maximum Dose
10 mg (max daily)
Investigational Product Name
Divigel 1 mg gel
Active Substance
Estradiol
Modality
Small molecule
Routes Of Administration
TRANSDERMAL USE
Route
TRANSDERMAL USE
Authorisation Status
Authorised (marketing authorisation number 13296, Sweden)
Dose Levels
maxDailyDoseAmount: 10 mg; maxTotalDoseAmount: 2100 mg; maxTreatmentPeriod: 7 (timeUnitCode 3)
Maximum Dose
10 mg (max daily)

Related trials

Other published trials that may interest you.